Connection
Bradley Haverkos to Lymphoma, B-Cell
This is a "connection" page, showing publications Bradley Haverkos has written about Lymphoma, B-Cell.
|
|
Connection Strength |
|
 |
|
 |
|
1.045 |
|
|
|
-
Haverkos B, Tyler K, Gru AA, Winardi FK, Frederickson J, Hastings J, Elkins C, Zhang X, Xu-Welliver M, Wong HK, Porcu P. Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University. Oncologist. 2015 Oct; 20(10):1161-6.
Score: 0.447
-
Epperla N, Zayac AS, Landsburg DJ, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman A, Li S, Medeiros LJ, Chang JE, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi Y, Bond DA, Evens AM, Naik SG, Kamdar M, Haverkos BM, Karmali R, Farooq U, Vose JM, Rubinstein P, Chaudhry A, Olszewski AJ. High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series. Blood Adv. 2024 10 22; 8(20):5355-5364.
Score: 0.211
-
Jodon G, Colton MD, Abbott D, Cai A, Haverkos B, Morgan R, Kamdar M. Clinical and Radiographic Predictors of Progression and Survival in Relapsed/Refractory Lymphoma Patients Receiving Anti-CD19 CAR T-cell Therapy. Clin Lymphoma Myeloma Leuk. 2023 01; 23(1):49-56.
Score: 0.183
-
Hwang S, Johnson A, Fabbro S, Hastings J, Haverkos B, Chung C, Porcu P, William B. Topical imiquimod monotherapy for indolent primary cutaneous B-cell lymphomas: a single-institution experience. Br J Dermatol. 2020 08; 183(2):386-387.
Score: 0.153
-
Colton M, Purev E, Haverkos B, Bair S, Jasem J, Jacob A, Kamdar M. Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):778-782.
Score: 0.052
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|